Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedFooter updates: added 'Revision: v3.3.3'; removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedPublication descriptions were updated to clarify that listed publications are provided voluntarily and are automatically filled from PubMed, and a new revision tag v3.3.2 was added.SummaryDifference0.2%

- Check29 days agoChange DetectedThe government funding lapse notice was removed from the page, eliminating the banner that previously directed users to opm.gov for status updates.SummaryDifference0.4%

- Check51 days agoChange DetectedAdded the Results section for KEYNOTE-087 with primary and secondary outcome measures and cohort-specific analyses (ORR, PFS, DOR, OS, etc.), along with a Publications subsection listing related articles. This update includes the final study results and associated literature.SummaryDifference0.4%

- Check73 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference3%

- Check80 days agoChange DetectedUpdate to bibliographic metadata: upgrade the citation to v3.1.0 and removal of an explicit erratum reference, indicating a versioned citation change with no new content added.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.